Targeting epigenetic programs in MLL-rearranged leukemias.

Rearrangements of the Mixed-Lineage Leukemia (MLL) gene are found in > 70% of infant leukemia, ~ 10% of adult acute myelogenous leukemia (AML), and many cases of secondary acute leukemias. The presence of an MLL rearrangement generally confers a poor prognosis. There are more than 60 known fusion partners of MLL having some correlation with disease phenotype and prognosis. The most common fusion proteins induce the inappropriate expression of homeotic (Hox) genes, which, during normal hematopoiesis, are maintained by wild-type MLL. MLL-rearranged leukemias display remarkable genomic stability, with very few gains or losses of chromosomal regions. This may be explained by recent studies suggesting that MLL-rearranged leukemias are largely driven by epigenetic dysregulation. Several epigenetic regulators that modify DNA or histones have been implicated in MLL-fusion driven leukemogenesis, including DNA methylation, histone acetylation, and histone methylation. The histone methyltransferase DOT1L has emerged as an important mediator of MLL-fusion-mediated leukemic transformation. The clinical development of targeted inhibitors of these epigenetic regulators may therefore hold promise for the treatment of MLL-rearranged leukemia.

[1]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[2]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[3]  Yi Zhang,et al.  DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. , 2011, Blood.

[4]  Dafydd G. Thomas,et al.  Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. , 2011, Blood.

[5]  J. Issa,et al.  Epigenetics in cancer: what's the future? , 2011, Oncology.

[6]  Kenneth H. Buetow,et al.  CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.

[7]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[8]  N. Zeleznik-Le,et al.  Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. , 2010, Cancer research.

[9]  Tina N. Davis,et al.  Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All , 2010 .

[10]  R. Stam,et al.  Connectivity Mapping Identifies HDAC Inhibitors as Suitable Candidates for the Treatment of t(4;11)-Positive Acute Lymphoblastic Leukemia In Infants , 2010 .

[11]  G. Mufti,et al.  Microsatellite Instability (MSI) In High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Cells Promotes Frameshift Mutations In DNA Repair Genes Indications for PARP Inhibitor Therapy , 2010 .

[12]  U. Popat,et al.  Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant. , 2010 .

[13]  Ali Shilatifard,et al.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis , 2010, Nature Reviews Cancer.

[14]  Todd D. Westergard,et al.  Phosphorylation of MLL by ATR is Required for Execution of Mammalian S Phase Checkpoint , 2010, Nature.

[15]  Thomas A. Milne,et al.  Pro Isomerization in MLL1 PHD3-Bromo Cassette Connects H3K4me Readout to CyP33 and HDAC-Mediated Repression , 2010, Cell.

[16]  Jiaying Tan,et al.  The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. , 2010, Cancer cell.

[17]  R. Irizarry,et al.  Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. , 2010, Blood.

[18]  A. Shilatifard,et al.  Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). , 2010, Genes & development.

[19]  M. Cleary,et al.  A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.

[20]  A. Shilatifard,et al.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. , 2010, Molecular cell.

[21]  R. Stam,et al.  Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. , 2009, Blood.

[22]  Tina N. Davis,et al.  DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia. , 2009 .

[23]  M. Gandhi,et al.  EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis. , 2009 .

[24]  A. Lane,et al.  Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Bach,et al.  Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia , 2009, PLoS biology.

[26]  R. Jaenisch,et al.  DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction , 2009, Nature Genetics.

[27]  S. Orkin,et al.  DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. , 2009, Cell stem cell.

[28]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[29]  Richard A Young,et al.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. , 2008, Genes & development.

[30]  K. Bhalla,et al.  Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. , 2008 .

[31]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[32]  N. Zeleznik-Le,et al.  Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. , 2008, Cancer research.

[33]  Christopher R. Vakoc,et al.  DOT1L/KMT4 Recruitment and H3K79 Methylation Are Ubiquitously Coupled with Gene Transcription in Mammalian Cells , 2008, Molecular and Cellular Biology.

[34]  T. Enver,et al.  Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia , 2008, Science.

[35]  A. Chinnaiyan,et al.  A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. , 2007, Blood.

[36]  J. Hess,et al.  The PHD fingers of MLL block MLL fusion protein-mediated transformation. , 2007, Blood.

[37]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[38]  M. Cleary,et al.  Protein arginine-methyltransferase-dependent oncogenesis , 2007, Nature Cell Biology.

[39]  J. Fisher,et al.  Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. , 2007, Cell stem cell.

[40]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[41]  S. Gore,et al.  DNA Demethylating Agents and Histone Deacetylase Inhibitors in Hematologic Malignancies , 2007, Cancer journal.

[42]  Wenzheng Zhang,et al.  Dot1a-AF9 Complex Mediates Histone H3 Lys-79 Hypermethylation and Repression of ENaCα in an Aldosterone-sensitive Manner* , 2006, Journal of Biological Chemistry.

[43]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[44]  S. Armstrong,et al.  Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia , 2006, Leukemia.

[45]  J. Hess,et al.  Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. , 2005, Cancer research.

[46]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[47]  T. Golub,et al.  Conditional MLL‐CBP targets GMP and models therapy‐related myeloproliferative disease , 2005, The EMBO journal.

[48]  O. Rozenblatt-Rosen,et al.  Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Downing,et al.  Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .

[50]  L. Zon,et al.  An Mll-Dependent Hox Program Drives Hematopoietic Progenitor Expansion , 2004, Current Biology.

[51]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[52]  S. Korsmeyer,et al.  Definitive hematopoiesis requires the mixed-lineage leukemia gene. , 2004, Developmental cell.

[53]  G. Kay,et al.  Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. , 2004, Molecular cell.

[54]  D. Gilliland,et al.  Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.

[55]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[56]  S. Armstrong,et al.  Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. , 2003, Blood.

[57]  N. Zeleznik-Le,et al.  MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Mathew,et al.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.

[59]  Rob Pieters,et al.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.

[60]  Toshiki Mori,et al.  ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. , 2002, Molecular cell.

[61]  Thomas A Milne,et al.  MLL targets SET domain methyltransferase activity to Hox gene promoters. , 2002, Molecular cell.

[62]  B. Owens,et al.  HOX and Non‐HOX Homeobox Genes in Leukemic Hematopoiesis , 2002, Stem cells.

[63]  J. Griffin,et al.  Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease , 2002, Oncogene.

[64]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[65]  C. Sawyers.  Rational therapeutic intervention in cancer: kinases as drug targets. , 2002, Current opinion in genetics & development.

[66]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[67]  M. Cleary,et al.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins , 2001, Oncogene.

[68]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[69]  C. Pui,et al.  Biological and therapeutic aspects of infant leukemia. , 2000, Blood.

[70]  M. Greaves,et al.  Prenatal origin of acute lymphoblastic leukaemia in children , 1999, The Lancet.

[71]  T. Komori,et al.  Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. , 1998, Blood.

[72]  C. Felix,et al.  RAS mutations in pediatric leukemias with MLL gene rearrangements , 1998, Genes, chromosomes & cancer.

[73]  S. Korsmeyer,et al.  Defects in yolk sac hematopoiesis in Mll-null embryos. , 1997, Blood.

[74]  T. Rabbitts,et al.  An Mll–AF9 Fusion Gene Made by Homologous Recombination Causes Acute Leukemia in Chimeric Mice: A Method to Create Fusion Oncogenes , 1996, Cell.

[75]  Keisuke Toyama,et al.  The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP96 and class I homeoprotein HOXA9 , 1996, Nature Genetics.

[76]  A. Feinberg,et al.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia , 1996, Nature Genetics.

[77]  S. Korsmeyer,et al.  Altered Hox expression and segmental identity in Mll-mutant mice , 1995, Nature.

[78]  C. Felix,et al.  ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. , 1995, Blood.

[79]  S. Korsmeyer,et al.  Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M. Greaves,et al.  In utero rearrangements in the trithorax-related oncogene in infant leukaemias , 1993, Nature.

[81]  H. Alder,et al.  The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene , 1992, Cell.

[82]  Michael L. Cleary,et al.  Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias , 1992, Cell.

[83]  J. Rowley,et al.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[84]  R. Arceci.  Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells , 2011 .

[85]  R. Arceci.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study , 2010 .

[86]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[87]  K. Davies,et al.  The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. , 2007, Human molecular genetics.

[88]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[89]  L. Silverman,et al.  Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. , 2010, Blood.